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OBJECTIVE — Insulin resistance is greater in racial/ethnic minorities than in non-Hispanic
whites(NHWs)forthosewithandwithouttype2diabetes.Becausepreviousresearchoninsulin
resistance in type 1 diabetes was limited to NHWs, racial/ethnic variation in an estimated
measure of insulin resistance in type 1 diabetes was determined.
RESEARCH DESIGN AND METHODS — The sample included 79 individuals with
type 1 diabetes diagnosed at age 18 years (32.9% NHWs, 46.8% non-Hispanic black [NHB],
7.6% other/mixed, and 12.7% Hispanic) and their families. Estimated glucose disposal rate
(eGDR) (milligrams per kilogram per minute; a lower eGDR indicates greater insulin resistance)
was calculated using A1C, waist circumference, and hypertension status.
RESULTS — Meancurrentagewas13.5years(range3.2–32.5)anddiabetesdurationwas5.7
years (0.1–19.9). eGDR was inversely associated with age. Compared with that in NHWs,
age-adjustedeGDRwassigniﬁcantlyloweramongnonwhites(NHB,other/mixed,andHispanic:
 1.83, P  0.0006). Age-adjusted eGDR was negatively associated with body fat, triglyc-
erides, urinary albumin/creatinine, acanthosis nigricans, parental obesity, and parental insulin
resistance and positively related to HDL and sex hormone–binding globulin. In multivariable
analysis, lower eGDR was signiﬁcantly associated with older age, nonwhite race/ethnicity, acan-
thosis, and lower HDL.
CONCLUSIONS — Minorities with type 1 diabetes are signiﬁcantly more insulin resistant,
as measured by eGDR, than NHWs. Exploring potential mechanisms, including disparities in
care and/or physiological variation, may contribute to preventing racial/ethnic differences in
insulin resistance–associated outcomes.
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nsulin resistance is common in type 2
diabetes (1) and seems to play a role in
the natural history (2) and risk of com-
plications (3) in type 1 diabetes as well.
Measurement of insulin resistance in type
1 diabetes is difﬁcult because methods
used in nondiabetic and type 2 individu-
als, e.g., insulin or homeostasis model
assessment (4), cannot be used in
hypoinsulinemia. The euglycemic-
hyperinsulinemic clamp has been used;
however,itislabor-intensiveandinvasive
and therefore is not suitable for popula-
tion-based studies. In response, a derived
measure of insulin resistance, the esti-
mated glucose disposal rate (eGDR), has
been developed using clinical measures
and is strongly correlated with clamp-
measured insulin resistance (5).
Consistent with clamp studies in type
1 diabetes (2), lower eGDR is associated
with older age (6), longer duration of di-
abetes (6), greater adiposity (6), family
history of type 2 diabetes (5), poor glyce-
mic control (5), and elevated lipids (6).
Low eGDR predicts incident retinopathy
(3), nephropathy (3,6), neuropathy (7),
and cardiovascular disease in type 1 diabe-
tes(3,6).Theseﬁndingsareprimarilybased
on non-Hispanic white (NHW) adults.
Previous research shows racial/ethnic
differences in insulin resistance for
healthy individuals and those with type 2
diabetes. For example, minority adults
with and without type 2 diabetes were
more insulin resistant than their NHW
counterparts (1,8). Similarly, in nondia-
betic youth, minorities were more insulin
resistant than NHWs (9,10). Despite
these ﬁndings, to our knowledge, there
arenodataoninsulinresistanceinminor-
ities with type 1 diabetes.
Therefore, we sought to determine 1)
whether racial/ethnic differences in insu-
linresistance,asmeasuredbyeGDR,exist
in type 1 diabetes and 2) whether the as-
sociation of eGDR with factors tradition-
ally related to insulin resistance differed
by race/ethnicity. It was hypothesized
that insulin resistance is greater in minor-
ities than in whites and that associations
with insulin resistance are consistent
across race/ethnicity.
RESEARCH DESIGN AND
METHODS— Racially/ethnically di-
verse individuals with diabetes diagnosed
at age 18 years and not due to another
condition were recruited through clinics,
health fairs, and mailings. All biological
ﬁrst-and second-degree relatives were in-
vited to participate. One hundred pro-
bands with childhood-onset diabetes
have participated with their families to
date; this analysis was restricted to those
with type 1 diabetes (n  79). Examina-
tions were conducted in the morning in
theUniversityofChicagoGeneralClinical
Research Center or in participants’
homes. The University of Chicago Insti-
tutional Review Board approved the
study. Participants aged 18 years and
parents of children aged 18 years pro-
vided written consent; children 10–17
years old assented.
Data collection and variables
Demographics/anthropometrics. Cur-
rent age, pubertal stage, race/ethnicity,
and head of household’s education and
employment were collected by question-
naire. Pubertal stage was self-assessed
with pubic hair Tanner diagrams, with
missing values (n  9) imputed using
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timates (11). Proband race/ethnicity was
deﬁnedasthatreportedfor3grandpar-
ents; if 3 grandparents shared the same
race/ethnicity, the proband was of mixed
origin. When race/ethnicity was available
on 3 grandparents, parental data were
used. If parental data were missing, pro-
band’s self-reported race/ethnicity was
used. Height was measured using a stadi-
ometer; percent body fat (10 years old)
and weight were measured with a bioel-
ectrical impedance analyzer scale (TBF-
300A;Tanita,ArlingtonHeights,IL).BMI
was transformed into Z scores using the
Centers for Disease Control and Preven-
tion Growth Chart (20 years old) (12)
andNationalHealthandNutritionExam-
ination Survey III (20 years old) (13)
age-and sex-matched reference data. Pro-
band overweight/obese was deﬁned as a
BMI Z score 1.04 (20 years old) or
BMI 25 kg/m
2 (20 years old) (12,13).
Parental obesity was deﬁned as BMI 30
kg/m
2. Waist circumference was mea-
sured twice and averaged.
Diabetes. Age at diagnosis was ab-
stracted from medical records; if unavail-
able, it was self-reported as were fre-
quency of insulin injections and parental
diabetes. Participants reporting 3 injec-
tions per day or use of a pump were de-
ﬁned as receiving an intensive insulin
regimen. Type 1 diabetes was deﬁned as
having 1) no C-peptide (n  69) or 2)
detectableC-peptidewith2yearsdura-
tion and either positive islet autoantibod-
ies (GAD, insulinoma-associated protein
2; n  10) or receiving intensive insulin
therapy (n  1). Fasting plasma C-
peptide was measured in all probands.
Those with a fasting blood glucose 150
mg/dl, measured by a glucometer (One-
Touch SureStep; LifeScan, Milpitas, CA),
also had a stimulated plasma C-peptide
measurement90minafteringestionofa6
ml/kg standard nutrient solution (Boost;
NovartisNutrition,Minneapolis,MN).C-
peptide in probands whose fasting glu-
cose was 150 mg/dl was considered
stimulated. C-peptide was determined
with a solid-phase, competitive chemilu-
minescent enzyme immunoassay (Immu-
lite 2000; Diagnostic Products, Bad
Nauheim, Germany) in the University of
Chicago Diabetes Research and Training
CenterLaboratory.Thelowerlimitofdetec-
tion was 0.17 nmol/l, and the intra-assay
coefﬁcientofvariation(CV)was8%.Absent
C-peptide was deﬁned as a fasting, and
stimulated if measured, level below the de-
tection limit. Antibodies to radiolabeled re-
combinant human GAD65 (whole) and
human insulinoma-associated protein 2
(349 amino acid cytoplasmic portion)
were quantiﬁed by a ﬂuid-phase immu-
noprecipitation assay.
Clinical measures. Current medica-
tions and typical sleep duration were col-
lected by questionnaire. Dyslipidemia
was deﬁned by 1) use of lipid-lowering
medications and/or 2) for participants
aged 20 years, total cholesterol 200
mg/dl, triglycerides 150 mg/dl, LDL
100 mg/dl, or HDL 59 mg/dl; and for
participants aged 20 years, total choles-
terol 170 mg/dl, triglycerides 150
mg/dl, LDL 110 mg/dl, or HDL 34
mg/dl. Blood pressure was measured
three times; the mean of the second and
third values was used. Hypertension was
deﬁned by 1) use of antihypertensive
medicationsand/or2)systolicbloodpres-
sure 140 mmHg and/or diastolic blood
pressure 90 mmHg for participants
aged 18 years old or systolic and/or di-
astolic blood pressure exceeding the age-,
sex-, and height-speciﬁc 95th percentile
(14) for those aged 18 years. Nephrop-
athy was deﬁned by 1) use of ACE inhib-
itors for kidney dysfunction and/or 2)a n
albumin-to-creatinine ratio 30 mg/g.
The Michigan Neuropathy Screening In-
strument examination was administered
by a physician; participants completed
theInstrument’squestionnaire.Neuropa-
thy was deﬁned by 1) a questionnaire
score 5 and/or 2) an examination score
2 (15). Acanthosis nigricans was as-
sessed by a physician.
Biospecimen measures. Fasting serum
insulin was measured with a solid-phase,
two-site chemiluminescent immunomet-
ric assay (Immulite 1000; Siemens Medi-
cal Solutions Diagnostics, Los Angeles,
CA) by the Diabetes Research and Train-
ing Center Laboratory. The intra-assay
CVs were 8.0%. The DCA 2000 ana-
lyzer (Bayer Healthcare, Elkhart, IN) was
used to measure A1C in whole blood and
urinary albumin and creatinine. A1C was
measured using a latex immunoagglutina-
tion inhibition method, and the intra- and
interassay CVs were 4.3%. The detec-
tion range for A1C was 2.5 to 14.0%. Al-
bumin and creatinine were measured
through a Benedict-Behre chemical reac-
tion, and the intra- and interassay CVs
were 6.6%.
Total cholesterol and HDL were mea-
sured in whole blood by the Cholestech
LDX System using reﬂectance photome-
try (Cholestech, Hayward, CA). LDL was
calculated using total cholesterol and
HDL. Triglycerides were also measured
by the Cholestech LDX System by an en-
zymatic method. For all cholesterol mea-
sures, the intra- and interassay CVs were
6.3%. C-reactive protein was measured
bytheUniversityofChicagoClinicalLab-
oratoryusingtheCRPLXimmunoturbidi-
metric assay (Roche Diagnostics,
Indianapolis, IN). The intra- and interas-
say CVs were 4.6%. An elevated level
was deﬁned as 3 mg/dl. The COT One
Step Cotinine Test Device (QuikTest
USA, Boca Raton, FL) was used to detect
urine cotinine using a lateral ﬂow chro-
matographic immunoassay. Positive coti-
nine was deﬁned as 200 ng/ml.
Serum leptin was determined by the
Diabetes Research and Training Center
Laboratory using the Human Leptin Ra-
dioimmunoassay kit (Millipore, St.
Charles, MO). The intra- and interassay
CVs were 7%. Serum adiponectin was
measured using the Human Adipokine
Panel A-3 Plex assay (Millipore) by Dr.
Mark Atkinson (University of Florida,
Gainesville, FL). The intra-assay CVs
were 1.4–7.9% and interassay CVs were
21%. Plasma total and free testosterone
and sex hormone–binding globulin
(SHBG) were measured in those aged
10 years old by the University of Chi-
cago Endocrine Laboratory. Total and
free testosterone were determined by a
solid-phase
125I radioimmunoassay (Sie-
mens Medical Solutions Diagnostics).
SHBG was measured with an assay stan-
dardized to the dialysis technique (16).
Intra-assay CVs were 10%.
Insulin resistance. Insulin resistance in
probands was assessed using eGDR, a mea-
sure derived from clamp studies in 24
NHW adults with long-standing type 1 di-
abetes using hypertension status, waist-to-
hip ratio, and glycemic control (5). Because
hip circumference was not available, the
comparable equation with waist circumfer-
ence was provided: eGDR (mg   kg
1  
min
1)  21.158  [3.407  hyperten-
sion status (yes  1; no  0)]  [0.090 
waistcircumference(cm)][0.551A1C
(%)]. eGDR was highly correlated with
clamp-measured insulin resistance (r 
0.79), and eGDR calculated using waist-
to-hip ratio or waist circumference was
highly correlated (r  0.87) (T.J. Or-
chard, University of Pittsburgh, per-
sonal communication, 2007). Lower
values indicate greater insulin resis-
tance. The range of clamp-measured
glucose disposal rates in the eGDR val-
idation study was 3.8 to 13.4, with a
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insulin resistance (5).
With the use of fasting insulin and
glucose, insulin resistance was deter-
minedintheparents(excludingfourwith
type 1 diabetes and two pregnant moth-
ers) by homeostasis model assessment,
version 2.0 (17). Parental insulin resis-
tance was deﬁned as a value 2.5 (4).
Statistical analyses
Analyses were performed in SAS (version
9.1; SAS Institute, Cary, NC); statistical
tests were considered signiﬁcant at P 
0.05. Racial/ethnic groups were com-
pared using t tests for continuous and 	
2
tests for categorical variables. The non-
white groups (NHB, other/mixed, and
Hispanic) were combined owing to small
sample sizes and similar mean eGDR. As-
sociations with eGDR were determined
usingunadjustedandmultivariablelinear
regression. Dummy variables were cre-
ated for categorical variables. Triglycer-
ides, albumin-to-creatinine ratio, and
leptinwerelog-transformed.Associations
of eGDR with hypertension, waist cir-
cumference, and A1C were not studied
because they were used to calculate
eGDR; the association with BMI Z score
was not analyzed because it was highly
correlated with waist circumference (r 
0.92, P  0.0001). The multivariable
model estimating eGDR was built by ﬁrst
entering all variables with P  0.15 from
theage-adjustedregressionsandthenusing
a stepwise approach to remove the nonsig-
niﬁcant covariates. Interactions with race/
ethnicity and age were tested, but none
were signiﬁcant. Age-adjusted logistic re-
gression tested the difference in hyperten-
sion prevalence by race/ethnicity.
RESULTS— For the 79 probands (Ta-
ble 1), mean current age was 13.5 years
(range 3.2–32.5); 32.9% were NHW,
46.8% were NHB, 7.6% were other/mixed,
and 12.7% were Hispanic. Mean disease
duration was 5.7 years (0.1–19.9), mean
currentA1Cwas9.1%,and69.6%werere-
ceiving an intensive insulin regimen. Only
six probands were overweight/obese (one
NHW, four NHB, and one other/mixed). A
large proportion had complications includ-
ingdyslipidemia(53.2%)andhypertension
(21.5%). More than two-thirds had at least
one obese parent, and 14.5% had at least
one parent who self-reported diabetes.
Mean eGDR was 9.05 mg   kg
1   min
1
(1.44–12.81).
Current age had an inverse associa-
tion with eGDR: eGDR (mg   kg
1  
min
1)  12.51  [0.26  age (years)]
(P  0.0001). Diabetes duration also had
an inverse association with eGDR: eGDR
(mg   kg
1   min
1)  10.15  [0.19 
duration (years)] (P  0.004). However,
the relationship with diabetes duration
was not signiﬁcant after adjusting for age.
eGDR did not differ by sex (Table 2).
Race/ethnicity was signiﬁcantly associ-
ated with eGDR even after adjustment for
age;comparedwithNHW,eGDRwassig-
niﬁcantly lower among nonwhites [mean
difference ()  1.83, P  0.0006].
With adjustment for age, eGDR had a
signiﬁcant negative association with per-
cent body fat (Table 2). Probands with at
least one obese parent had signiﬁcantly
lower eGDR levels than those with no
obese parent ( 2.42, P  0.0001);
further adjustment for probands’ percent
body fat did not attenuate this associa-
tion. Probands with at least one insulin-
resistant parent also had signiﬁcantly
lower eGDR than those with no insulin-
resistant parent ( 1.79, P  0.03);
however,parentalself-reporteddiabetes
status was not associated with proband
eGDR. eGDR was positively associated
with HDL and negatively associated
with triglycerides and albumin-to-
creatinine ratio. Total cholesterol, LDL,
and neuropathy were not related to
eGDR. Participants with acanthosis nig-
ricans and those with elevated C-reac-
tive protein had signiﬁcantly lower
eGDR compared with those without
( 2.06, P  0.0002, and 
1.84,P  0.04,respectively).Inthose
with body fat determined (10 years
old, n  57), the association of eGDR
with C-reactive protein was also signif-
icant, but the relationship became non-
signiﬁcantafteradjustmentforbodyfat.
Both leptin and adiponectin were
negatively associated with eGDR, but af-
ter controlling for age, adiponectin was
no longer signiﬁcant (Table 2). Further,
for the subgroup of probands with body
fat determined (n  51), leptin was neg-
atively associated with eGDR, but subse-
Table 1—Description of probands with type 1 diabetes
All NHW Nonwhite P
n 79 26 53
Demographics
Current age (years) 13.5 
 5.7 13.3 
 6.4 13.6 
 5.4 0.81
Age range (years) 3.2–32.5 4.4–32.5 3.2–27.0
Female sex (%) 53.2 38.5 60.4 0.07
Head of household education high
school (%) 27.9 7.7 37.7 0.005
Anthropometrics
BMI Z score (SD units) 0.7 
 0.8 1.0 
 0.5 0.6 
 0.9 0.04
Waist circumference (cm) 70.9 
 15.0 67.7 
 10.9 72.4 
 16.5 0.20
Body fat (percentage unit) (n  57)* 27.1 
 10.2 21.5 
 7.6 30.1 
 10.2 0.002
1 or 2 obese parents (%) (n  61)† 67.2 44.0 83.3 0.001
Diabetes
Duration (years) 5.7 
 4.5 5.3 
 4.6 5.8 
 4.5 0.66
Duration range (years) 0.1–19.9 0.4–19.9 0.1–17.7
Intensive insulin therapy (%) 69.6 96.2 56.6 0.0003
A1C (percentage unit) 9.1 
 2.2 7.9 
 1.7 9.7 
 2.2 0.0004
1 or 2 parents with insulin resistance
(%) (n  51)† 27.5 17.4 35.7 0.15
1 or 2 parents with diabetes (%)
(n  76)† 14.5 19.2 12.0 0.40
Clinical measures
Dyslipidemia (%) 53.2 34.6 62.3 0.02
Hypertension (%) 21.5 11.5 26.4 0.13
Nephropathy (%) 11.4 3.9 15.1 0.14
Neuropathy (%) 17.7 23.1 15.1 0.38
Any acanthosis (%) 29.1 7.7 39.6 0.003
Elevated C-reactive protein (%) 10.1 3.9 13.2 0.20
eGDR (mg   kg
1   min
1) 9.05 
 2.71 10.34 
 2.16 8.42 
 2.74 0.003
Data are means 
 SD or percentages. n  79. Racial/ethnic groups were compared using t and 	
2 tests.
*Subgroup 10 years old. †Subgroups with respective data for parents available.
Racial/ethnic differences in insulin resistance
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attenuated this association. In stratiﬁed
analyses, SHBG was positively associated
with eGDR in both sexes and remained
signiﬁcant in women after controlling for
age. Among all probands, there was a sig-
niﬁcant age- and sex-adjusted positive as-
sociation between eGDR and SHBG
(regression coefﬁcient  0.96 mg   kg
1
min
1 rise in eGDR per 10 nmol/l in-
crease in SHBG, P  0.0001); additional
adjustment for proband percent body fat
did not change this association.
In multivariable analysis (Table 3),
lower eGDR was signiﬁcantly associated
with older age, nonwhite race/ethnicity,
andacanthosis.WhenHDLwasincluded,
resulting in a smaller sample size, these
associations remained signiﬁcant. In ad-
dition, lower eGDR was signiﬁcantly as-
sociated with lower HDL. The potential
confounding effects of probands’ percent
body fat, parental obesity, and parental
insulin resistance on these associations
were examined and found not to occur
nor did race/ethnicity modify the associ-
ations of eGDR with these factors. The
independent variables in the multivari-
able models explained 46–50% of the
variance in eGDR.
Whether the racial/ethnic variation in
eGDR was driven by differences in the
components used to calculate eGDR was
explored. With adjustment for age, com-
paredwithNHWparticipants,nonwhites
had signiﬁcantly higher A1C and a trend
for larger waist circumference (9.7 vs.
7.9%, P  0.0005, and 72.2 vs. 68.2 cm,
P  0.10, respectively; estimates at mean
age of 13.5 years), and a trend toward a
higher prevalence of hypertension (26.4
vs. 11.5%, odds ratio 3.1, P  0.10).
CONCLUSIONS — Insulin resis-
tance is an important component of type
1 diabetes (2). To our knowledge, this is
the ﬁrst study to show that racial/ethnic
differences in insulin resistance, as mea-
sured by eGDR, exist in this group. Fur-
thermore,thisvariationwasobservedina
sample of young individuals with short
diabetes duration and normal adiposity,
suggesting that racial/ethnic differences
are present early in the disease course.
The current results are consistent
withpreviousresearchinhealthyindivid-
uals and in those with type 2 diabetes of
whom nonwhite groups were generally
more insulin resistant. Speciﬁcally, non-
diabetic African American and Hispanic
adults were more insulin resistant than
nondiabetic NHW adults, using a fre-
Table 2—Associations of eGDR with demographic, anthropometric, diabetes, clinical, and
hormonal characteristics in probands with type 1 diabetes
Unadjusted Age-adjusted
Regression
coefﬁcient P*
Regression
coefﬁcient P
Demographic
Tanner stage (pubic hair; vs. 1) 0.0001†
2 0.27 0.35
3 2.62 0.001 1.79
4 2.13 0.004 1.14
5 3.96 0.0001 2.30
Female sex (vs. male) 0.63 0.01
Nonwhite (vs. NHW) 1.92 0.003 1.83 0.0006
Head of household education (vs. high
school) 0.01† 0.007†
High school graduate 0.14 0.15
Some college 1.37 1.67 0.04
College graduate 2.67 0.01 2.36 0.008
Professional school 2.28 1.88
Head of household working (vs. not working) 0.58 0.29
Anthropometric
Body fat (10 percentage units) (n  57)‡ 0.90 0.01 0.76 0.03
1 or 2 obese parents (n  61)§ 3.01 0.0001 2.42 0.0001
Diabetes
Age at diagnosis (years) 0.24 0.0005 0.05
Intensive insulin therapy 0.71 0.70
1 or 2 parents with insulin resistance (n  51)§ 2.52 0.004 1.79 0.03
1 or 2 parents with diabetes (n  76)§ 1.90 0.03 1.32
Clinical
Total cholesterol (10 mg/dl) 0.14 0.04 0.08
LDL (10 mg/dl; n  61) 0.15 0.12
HDL (10 mg/dl; n  68) 0.50 0.008 0.38 0.02
Triglycerides (mg/dl; log transformed) 2.58 0.0002 1.60 0.01
Dyslipidemia present 0.79 0.71
Albumin-to-creatinine ratio (mg/g;
log-transformed) 1.05 0.001 0.73 0.01
Nephropathy present 2.92 0.002 1.64 0.04
Neuropathy present 1.17 0.28
Any acanthosis present 2.54 0.0001 2.06 0.0002
Elevated C-reactive protein 3.20 0.001 1.84 0.04
Positive cotinine 2.66 0.01 1.13
Average sleep duration (hours) 0.45 0.007 0.19
Hormonal
Leptin (ng/ml; log-transformed) (n  71) 1.16 0.0001 0.57 0.04
Adiponectin (10 g/ml) (n  45) 0.34 0.03 0.17
Total testosterone (10 ng/dl)‡
Female subjects (n  31) 0.10 0.10
Male subjects (n  24) 0.03 0.00
Free testosterone (10 pg/ml)‡
Female subjects (n  31) 0.07 0.04
Male subjects (n  24) 0.14 0.05
SHBG (10 nmol/l)‡
Female subjects (n  31) 0.86 0.02 1.10 0.004
Male subjects (n  24) 1.04 0.008 0.68
N  79. eGDR in milligrams per kilogram per minute. *P values are speciﬁed if 0.05. †P value for overall
effect. ‡Subgroup 10 years old. §Subgroups with respective data for parents available.
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erance test with minimal model analysis
(8). For adults with type 2 diabetes, Af-
rican Americans, but not Hispanics,
were more insulin resistant than NHW
(1). The picture may be more compli-
catedinadolescence,becausepubertyis
an insulin-resistant state (10). One
study demonstrated that Mexican
American, but not black, children were
moreinsulin-resistantthanNHWyouth
as measured by homeostasis model as-
sessment(9),whereasanotherstudyus-
ing the clamp method found that
insulin resistance was increased in
black but not white participants be-
tween 11 and 19 years of age (10).
Our results demonstrating trends for
racial/ethnic differences in the eGDR
components are also consistent with the
literature, with minorities demonstrating
poorer outcomes. For example, African
American children with type 1 diabetes
have worse glycemic control than white
children with diabetes (18). With regard
to adiposity, a higher percentage of Mex-
ican-American and black adolescents are
overweight/obese compared with NHW
adolescents (9). The National Health and
Nutrition Examination Survey III also
found that African American adult
womenwithtype2diabeteshaveahigher
BMI than NHW women with diabetes
(19).Last,hypertensionismoreprevalent
in African American adults than in NHW
and Mexican American adults, both with
and without type 2 diabetes (20).
Several clinical characteristics are as-
sociated with insulin resistance in type 1
diabetes. For example, higher insulin re-
sistance is related to older age and longer
disease duration (6). The authors found
similar relationships, but the association
with age was stronger and duration was
no longer signiﬁcant after adjustment for
age. Family history of type 2 diabetes has
been shown to be associated with greater
insulin resistance in those with type 1 di-
abetes (5). In the current study, there was
no association with parental history of di-
abetes, which was based on self-report.
However, parental obesity and parental
insulin resistance, which were directly
measured in the current study and are
risk factors for diabetes, were related to
greater proband age-adjusted insulin
resistance. This association was inde-
pendent of the probands’ adiposity,
indicating that other familial character-
istics in addition to factors affecting
probands’ body composition (e.g., ge-
netic predisposition) may inﬂuence
their insulin resistance.
As may be expected, acanthosis nigri-
cans was related to greater insulin resis-
tance. Lower levels of SHBG were also
signiﬁcantly associated with greater insu-
lin resistance in age-adjusted analysis.
This ﬁnding is consistent with basic sci-
ence (21) and clinical research (22) dem-
onstrating a negative association between
insulin and SHBG levels, such that the
greaterthelevelofinsulinresistanceinan
individual with type 1 diabetes is, the
higheristheinsulindoserequiredtomeet
physiological requirements and the lower
the hepatic production of SHBG. These
results suggest that the derived measure
of insulin resistance, eGDR, is indeed
measuringinsulinresistanceinthosewith
type 1 diabetes.
The risk of micro-and macrovascular
complications is elevated for individuals
with type 1 diabetes who have insulin
resistance. For example, greater insulin
resistance is associated with the develop-
ment of nephropathy (3,6), neuropathy
(7), and elevated lipids (6). In the current
study, higher insulin resistance was asso-
ciated with prevalent dyslipidemia and
nephropathy. It could be argued that
these relationships may be capturing the
well-established associations of diabetes
complications with the components used
to calculate eGDR, speciﬁcally subopti-
mal glycemic control and/or hyperten-
sion. However, previous research in
NHW adults with long-standing type 1
diabetes showed that insulin resistance as
measured by eGDR more strongly pre-
dicted overt diabetic nephropathy than
did glycemia or blood pressure (23).
Therewerenodifferencesininsulinresis-
tance by prevalent neuropathy.
eGDR is a derived measure of insulin
resistance, and clamp techniques are
needed to conﬁrm our results. However,
because eGDR is noninvasive and
strongly correlated with clamp-measured
insulin resistance, it is useful for popula-
tion-based studies, similar to the numer-
ous surrogate measures of insulin
resistance that are commonly used in
studies of type 2 diabetic and nondiabetic
groups. We demonstrated for the ﬁrst
timeassociationsofprobandinsulinresis-
tance with parental obesity and parental
insulin resistance, although there may
have been limited power to conﬁrm the
associations in the multivariable model.
Limited sample size may also explain the
lack of a signiﬁcant difference in insulin
resistance by neuropathy status, although
themagnitudeofthedifferencewassmall.
Last, because we combined nonwhite
groups owing to small sample sizes and
similar eGDR, we may have limited the
ability to detect interactions by race/
ethnicity. The research had a number of
strengths, most importantly that it is the
ﬁrst study of type 1 diabetes, to our
knowledge, to examine insulin resistance
using a racially/ethnically diverse sample.
We were also able to evaluate and adjust
for confounders in the multivariable
model to estimate the independent asso-
ciation of race/ethnicity with insulin
resistance.
The greater insulin resistance ob-
served in nonwhites with type 1 diabetes
may help clarify the well-documented
gaps in diabetes outcomes for under-
served minorities. Insulin resistance is as-
sociated with a spectrum of poor health
outcomes; thus, the greater insulin resis-
tance in minorities with type 1 diabetes
may explain their higher incidence of di-
abetes-related complications compared
Table 3—Multivariable model for eGDR in probands with type 1 diabetes
Regression
coefﬁcient P
Model 1: n  79, R
2  0.46
Current age (years) 0.23 0.0001
Nonwhite (vs. NHW) 1.33 0.01
Any acanthosis present 1.60 0.004
Model 2: n  68, R
2  0.50
Current age (years) 0.21 0.0001
Nonwhite (vs. NHW) 1.60 0.006
Any acanthosis present 1.30 0.03
HDL (10 mg/dl) 0.39 0.009
N  79. eGDR in milligrams per kilogram per minute. Variables entered into the model: current age,
race/ethnicity, head of household education, percent body fat, parental obesity, parental insulin resistance,
HDL, triglycerides, albumin-to-creatinine ratio, acanthosis, elevated C-reactive protein, positive cotinine,
sleep duration, and SHBG.
Racial/ethnic differences in insulin resistance
618 DIABETES CARE, VOLUME 33, NUMBER 3, MARCH 2010 care.diabetesjournals.orgwith NHW (24). Future research is
needed to determine which factors con-
tributetoracial/ethnicdifferencesininsu-
lin resistance in this group, such as
disparities in diabetes care, differences in
behaviors, environmental factors, or
physiological processes, or simply resid-
ual confounding. Understanding which
modiﬁable factors prevent insulin resis-
tance and then targeting interventions to
those groups most at risk will help ad-
dress the public health burden of type 1
diabetesanditscomplicationsinminority
populations.
In summary, insulin resistance as es-
timated by eGDR was greater in minori-
ties with type 1 diabetes than in NHW
probands. Because there exists a strong
association between insulin resistance
andpoorhealthoutcomesindiabetes,the
search for effective interventions to im-
proveinsulinresistanceinminoritieswith
type 1 diabetes must become a priority.
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